New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 29, 2018 - Acadia Pharmaceuticals announced the FDA approval of Nuplazid (pimavanserin) 34 mg capsules for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Download PDF
Return to publications
